Avanti il prossimo

Riproduzione automatica

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Visualizzazioni • 07/14/23
Condividere
Incorporare
administrator
administrator
Iscritti
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Mostra di più
0 Commenti sort Ordina per
Commenti su Facebook

Avanti il prossimo

Riproduzione automatica